Emerging role of GLP-1 receptor agonists in the treatment of obesity

References

• Flegal KM Carroll MD Ogden CL Curtin LR Prevalence and trends in obesity among US adults, 1999–2008 JAMA 2010 303 3 235 241 20071471
   PubMed Web of Science ®Google Scholar
• Kuczmarski RJ Flegal KM Campbell SM Johnson CL Increasing prevalence of overweight among US adults: The National Health and Nutrition Examination Surveys, 1960 to 1991 JAMA 1994 272 205 211 8022039
   PubMed Web of Science ®Google Scholar
• Dansinger ML Gleason JA Griffith JL Selker HP Schaefer EJ Comparison of the Atkins, Ornish, Weight Watchers, and Zone diets for weight loss and heart disease risk reduction: A randomized trial JAMA 2005 293 43 53 15632335
   PubMed Web of Science ®Google Scholar
• Brinkworth GD Wycherley TP Noakes M Clifton PM Reductions in blood pressure following energy restriction for weight loss do not rebound after re-establishment of energy balance in overweight and obese subjects Clin Exp Hypertens 2008 30 385 396 18633761
   PubMed Web of Science ®Google Scholar
• Hamman RF Wing RR Edelstein SL Effect of weight loss with lifestyle intervention on risk of diabetes Diabetes Care 2006 29 2102 2107 16936160
   PubMed Web of Science ®Google Scholar
• Wadden TA Berkowitz RI Womble LG Randomized trial of lifestyle modification and pharmacotherapy for obesity N Engl J Med 2005 353 2111 2120 16291981
   PubMed Web of Science ®Google Scholar
• Richelsen BR Tonstad S Rassner S Effect of orlistat on weight regain and cardiovascular risk factors following a very-low-energy diet in abdominally obese patients Diabetes Care 2007 30 27 32 17192328
   PubMed Web of Science ®Google Scholar
• Arterburn D Crane P Veenstra D The eff icacy and safety of sibutramine for weight loss: A systematic review Arch Intern Med 2004 164 994 1003 15136309
   PubMed Web of Science ®Google Scholar
• Hutton B Fergusson D Changes in body weight and serum lipid profile in obese patients treated with orlistat in addition to a hypocaloric diet: A systematic review of randomized clinical trials Am J Clin Nutr 2004 80 1461 1468 15585756
   PubMed Web of Science ®Google Scholar
• Padwal R Li S Lau D Long-term pharmacotherapy for obesity and overweight Cochrane Database Syst Rev 2003 4 CD004094 14584004
   PubMedGoogle Scholar
• Vettor R Serra R Fabris R Pagano C Federspil G Effect of sibutramine on weight management and metabolic control in Type 2 diabetes Diabetes Care 2005 28 942 949 15793204
   PubMed Web of Science ®Google Scholar
• Li Z Maglione M Tu W Meta-analysis: Pharmacologic treatment of obesity Ann Intern Med 2005 142 532 546 15809465
   PubMed Web of Science ®Google Scholar
• Eissele R Goke R Willemer S Glucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat, pig and man Eur J Clin Invest 1992 22 283 291 1499644
   PubMed Web of Science ®Google Scholar
• Mortensen K Christensen LL Holst JJ Orskov C GLP-1 and GIP are colocalized in a subset of endocrine cells in the small intestine Regul Pept 2003 114 189 196 12832109
   PubMed Web of Science ®Google Scholar
• Hermann C Goke R Richter G Fehmann H Arnold R Goke B Glucagon- like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients Digestion 1995 56 117 126 7750665
   PubMed Web of Science ®Google Scholar
• Holst J The physiology of glucagon-like peptide 1 Physiol Rev 2007 87 1409 1439 17928588
   PubMed Web of Science ®Google Scholar
• Nakagawa A Satake H Nakabayashi H Receptor gene expression of glucagon-like peptide-1, but not glucose-dependent insulinotropic polypeptide, in rat nodose ganglion cells Auton Neurosci 2004 110 36 43 14766323
   PubMed Web of Science ®Google Scholar
• Bucinskaite V Tolessa T Pedersen J Receptor-mediated activation of gastric vagal afferents by glucagon-like peptide-1 in the rat Neurogastroenterol Motil 2009 21 978 e78 19453518
   PubMed Web of Science ®Google Scholar
• Doyle M Egan J Mechanisms of action of glucagon-like peptide 1 in the pancreas Pharmacol Ther 2007 113 546 593 17306374
   PubMed Web of Science ®Google Scholar
• Hare K Knop F Asmar M Preserved inhibitory potency of GLP-1 on glucagon secretion in Type 2 diabetes mellitus J Clin Endocrinol Metab 2009 94 4679 4687 19837930
   PubMed Web of Science ®Google Scholar
• Göke R Larsen P Mikkelsen J Sheikh S Distribution of GLP-1 binding sites in the rat brain: Evidence that exendin-4 is a ligand of brain GLP-1 binding sites Eur J Neurosci 1995 7 2294 2300 8563978
   PubMed Web of Science ®Google Scholar
• Kastin A Akerstrom V Pan W Interactions of glucagon-like peptide-1 (GLP-1) with the blood-brain barrier J Mol Neurosci 2002 18 7 14 11931352
   PubMed Web of Science ®Google Scholar
• Hassan M Eskilsson A Nilsson C In vivo dynamic distribution of 131I-glucagon-like peptide-1 (7–36) amide in the rat studied by gamma camera Nucl Med Biol 1999 26 413 420 10382845
   PubMed Web of Science ®Google Scholar
• Pannacciulli N Le D Salbe A Postprandial glucagon-like peptide-1 (GLP-1) response is positively associated with changes in neuronal activity of brain areas implicated in satiety and food intake regulation in humans Neuroimage 2007 35 511 517 17317222
   PubMed Web of Science ®Google Scholar
• Abbott CR Monteiro M Small CJ The inhibitory effects of peripheral administration of peptide YY3-36 and glucagon-like peptide- 1 on food intake are attenuated by ablation of the vagal-brainstem-hypothalamic pathway Brain Res 2005 1044 127 131 15862798
   PubMed Web of Science ®Google Scholar
• Turton M O’Shea D Gunn I A role for glucagon-like peptide-1 in the central regulation of feeding Nature 1996 379 69 72 8538742
   PubMed Web of Science ®Google Scholar
• Hwa JJ Ghibaudi L Williams P Witten MB Tedesco R Strader CD Differential effects of intracerebroventricular glucagon-like peptide-1 on feeding and energy expenditure regulation Peptides 1998 19 869 875 9663452
   PubMed Web of Science ®Google Scholar
• Flint A Raben A Astrup A Holst J Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans J Clin Invest 1998 101 515 520 9449682
   PubMed Web of Science ®Google Scholar
• Verdich C Flint A Gutzwiller J A meta-analysis of the effect of glucagon-like peptide-1 (7–36) amide on ad libitum energy intake in humans J Clin Endocrinol Metab 2001 86 4382 4389 11549680
   PubMed Web of Science ®Google Scholar
• Meeran K O’Shea D Edwards CMB Repeated intracerebroventricular administration of glucagon-like peptide-1-(7–36) amide or exendin-(9–39) alters body weight in the rat Endocrinology 1999 140 244 250 9886831
   PubMed Web of Science ®Google Scholar
• Zander M Madsbad S Madsen JL Holst JJ Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and [beta]-cell function in type 2 diabetes: A parallel-group study Lancet 2002 359 824 830 11897280
   PubMed Web of Science ®Google Scholar
• Scrocchi L Brown T MaClusky N Glucose intolerance but normal satiety in mice with a null mutation in the glucago-like peptide 1 receptor gene Nat Med 1996 2 1254 1258 8898756
   PubMed Web of Science ®Google Scholar
• Osaka T Endo M Yamakawa M Inoue S Energy expenditure by intravenous administration of glucagon-like peptide-1 mediated by the lower brainstem and sympathoadrenal system Peptides 2005 26 1623 1631 16112402
   PubMed Web of Science ®Google Scholar
• Pannacciulli N Bunt JC Koska J Bogardus C Krakoff J Higher fasting plasma concentrations of glucagon-like peptide 1 are associated with higher resting energy expenditure and fat oxidation rates in humans Am J Clin Nutr 2006 84 556 560 16960169
   PubMed Web of Science ®Google Scholar
• Shalev A Holst J Keller U Effects of glucagon-like peptide 1 (7–36 amide) on whole-body protein metabolism in healthy man Eur J Clin Invest 1997 27 10 16 9041371
   PubMed Web of Science ®Google Scholar
• Flint A Raben A Ersboll A Holst J Astrup A The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity Int J Obes Relat Metab Disord 2001 25 781 792 11439290
   PubMed Web of Science ®Google Scholar
• Flint A Raben A Rehfeld J Holst J Astrup A The effect of glucagonlike peptide-1 on energy expenditure and substrate metabolism in humans Int J Obes Relat Metab Disord 2000 24 288 298 10757621
   PubMed Web of Science ®Google Scholar
• Ranganath L Beety J Morgan L Wright J Howland R Marks V Attenuated GLP-1 secretion in obesity: Cause or consequence? Gut 1996 38 916 919 8984033
   PubMed Web of Science ®Google Scholar
• Verdich C Toubro S Buemann B Madsen J Holst J Astrup A The role of postprandial releases of insulin and incretin hormones in meal-induced satiety – effect of obesity and weight reduction Int J Obes 2001 25 1206 1214
   PubMed Web of Science ®Google Scholar
• Vilsboll T Agerso H Krarup T Holst J Similar elimination rates of glucagon-like peptide-1 in obese Type 2 diabetic patients and healthy subjects J Clin Endocrinol Metab 2003 88 220 224 12519856
   PubMed Web of Science ®Google Scholar
• Eng J Kleinman WA Singh L Singh G Raufman JP Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas J Biol Chem 1992 267 7402 7405 1313797
   PubMed Web of Science ®Google Scholar
• Linnebjerg H Kothare P Park S Effect of renal impairment on the pharmacokinetics of exenatide Br J Clin Pharmacol 2007 64 317 327 17425627
   PubMed Web of Science ®Google Scholar
• Buse J Henry R Han J Kim D Fineman M Baron A Group E-CS Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with Type 2 diabetes Diabetes Care 2004 27 2628 2635 15504997
   PubMed Web of Science ®Google Scholar
• Kendall D Riddle M Rosenstock J Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with Type 2 diabetes treated with metformin and a sulfonylurea Diabetes Care 2005 28 1083 1091 15855571
   PubMed Web of Science ®Google Scholar
• DeFronzo R Ratner R Han J Kim D Fineman M Baron A Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes Diabetes Care 2005 28 1092 1100 15855572
   PubMed Web of Science ®Google Scholar
• Heine RJ Van Gaal LF Johns D Mihm MJ Widel MH Brodows RG Exenatide versus insulin glargine in patients with suboptimally controlled Type 2 diabetes Ann Intern Med 2005 143 559 569 16230722
   PubMed Web of Science ®Google Scholar
• Nauck M Duran S Kim D A comparison of twice-daily exenatide and biphasic insulin aspart in patients with Type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: A noninferiority study Diabetologia 2007 50 259 267 17160407
   PubMed Web of Science ®Google Scholar
• Zinman B Hoogwerf B Durán García S The effect of adding exenatide to a thiazolidinedione in suboptimally controlled Type 2 diabetes: A randomized trial Ann Intern Med 2007 146 477 485 17404349
   PubMed Web of Science ®Google Scholar
• Barnett A Burger J Johns D Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with Type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: A multinational, randomized, open-label, two-period, crossover noninferiority trial Clin Ther 2007 29 2333 2348 18158075
   PubMed Web of Science ®Google Scholar
• Moretto TJ Milton DR Ridge TD Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: A randomized, double-blind, placebo-controlled, parallel-group study Clin Ther 2008 30 1448 1460 18803987
   PubMed Web of Science ®Google Scholar
• Bunck M Diamant M Cornér A One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated Type 2 diabetic patients: A randomized, controlled trial Diabetes Care 2009 32 762 768 19196887
   PubMed Web of Science ®Google Scholar
• Davies M Donnelly R Barnett A Jones S Nicolay C Kilcoyne A Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with Type 2 diabetes: Results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study Diabetes Obes Metab 2009 11 1153 1162 19930005
   PubMed Web of Science ®Google Scholar
• Buse JB Rosenstock J Sesti G Liraglutide once a day versus exenatide twice a day for Type 2 diabetes: A 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6) Lancet 2009 374 39 47 19515413
   PubMed Web of Science ®Google Scholar
• Buse JB Klonoff DC Nielsen LL Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with Type 2 diabetes: An interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials Clin Ther 2007 29 139 153 17379054
   PubMed Web of Science ®Google Scholar
• Klonoff DC Buse JB Nielsen LL Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with Type 2 diabetes treated for at least 3 years Curr Med Res Opin 2008 24 275 286 18053320
   PubMed Web of Science ®Google Scholar
• Bhushan R Elkind-Hirsch KE Bhushan M Butler W Duncan K Marrioneaux O Exenatide use in the management of metabolic syndrome: A retrospective database study Endocr Pract 2009 14 993 999 19095598
   PubMedGoogle Scholar
• Trautmann M Northrup J Glass L Cao D Holcombe J OR14-1: Exenatide treatment added to a lifestyle modification program was associated with body weight reduction in obese patients Abstract presented at the 2009 annual meeting of the Endocrine Society Washington DC June 10–13, 2009
   Google Scholar
• Drucker DJ Buse JB Taylor K Exenatide once weekly versus twice daily for the treatment of Type 2 diabetes: A randomised, open-label, non-inferiority study Lancet 2008 372 1240 1250 18782641
   PubMed Web of Science ®Google Scholar
• Kim D MacConell L Zhuang D Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with Type 2 diabetes Diabetes Care 2007 30 1487 1493 17353504
   PubMed Web of Science ®Google Scholar
• Buse JB Drucker DJ Taylor KL DURATION-1: Exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks Diabetes Care March 9 2010 [Epub ahead of print]
   Web of Science ®Google Scholar
• Best JH Boye KS Rubin RR Cao D Kim TH Peyrot M Improved treatment satisfaction and weight-related quality of life with exenatide once weekly or twice daily Diabet Med 2009 26 7 722 728 19573122
   PubMed Web of Science ®Google Scholar
• Bain SC Stephens JW Exenatide and pancreatitis: An update Expert Opin Drug Saf 2008 7 6 643 644 18983211
   PubMed Web of Science ®Google Scholar
• Ayoub W Kumar A Naguib H Taylor H Exenatide-induced acute pancreatitis Endocr Pract 2010 16 80 83 19703814
   PubMed Web of Science ®Google Scholar
• Byetta package insert Amylin Pharmaceuticals and Eli Lilly Co Available at: www.byetta.com Accessed on March 15, 2010
   Google Scholar
• Weise WJ Sivanandy MS Block CA Comi RJ Exenatide-associated ischemic renal failure Diabetes Care 2009 32 e22 e23 19171732
   PubMedGoogle Scholar
• Viswanathan P Chaudhuri A Bhatia R Al-Atrash F Mohanty P Dandona P Exenatide therapy in obese patients with Type 2 diabetes mellitus treated with insulin Endocr Pract 2007 13 444 450 17872344
   PubMedGoogle Scholar
• Sheffield C Kane M Busch R Bakst G Abelseth J Hamilton R Safety and efficacy of exenatide in combination with insulin in patients with Type 2 diabetes mellitus Endocr Pract 2008 14 285 292 18463034
   PubMedGoogle Scholar
• Yoon NM Cavaghan MK Brunelle RL Roach P Exenatide added to insulin therapy: A retrospective review of clinical practice over two years in an academic endocrinology outpatient setting Clin Ther 2009 31 1511 1523 19695400
   PubMed Web of Science ®Google Scholar
• Secnik Boye K Matza L Oglesby A Patient-reported outcomes in a trial of exenatide and insulin glargine for the treatment of Type 2 diabetes Health Qual Life Outcomes 2006 4 80 17034640
   PubMed Web of Science ®Google Scholar
• King AB Wolfe G Healy S Clinical observations of exenatide treatment Diabetes Care 2006 29 8 1984 16873820
   PubMed Web of Science ®Google Scholar
• Victoza® package insert Novo Nordisk Available from: www.victoza.com Accessed on Mar 15, 2010
   Google Scholar
• Vilsboll T Zdravkovic M Le-Thi T Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with Type 2 diabetes Diabetes Care 2007 30 1608 1610 17372153
   PubMed Web of Science ®Google Scholar
• Garber A Henry R Ratner R Garcia-Hernandez PA Liraglutide versus glimepiride monotherapy for Type 2 diabetes (LEAD-3 Mono): A randomised, 52-week, Phase III, double-blind, parallel-treatment trial Lancet 2009 373 473 481 18819705
   PubMed Web of Science ®Google Scholar
• Nauck M Frid A Hermansen K Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in Type 2 diabetes Diabetes Care 2009 32 84 90 18931095
   PubMed Web of Science ®Google Scholar
• Zinman B Gerich J Buse JB Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with Type 2 diabetes (LEAD-4 Met + TZD) Diabetes Care 2009 32 1224 1230 19289857
   PubMed Web of Science ®Google Scholar
• Marre M Shaw J Brändle M Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU) Diabet Med 2009 26 268 278 19317822
   PubMed Web of Science ®Google Scholar
• Russell-Jones D Vaag A Schmitz O Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in Type 2 diabetes mellitus (LEAD-5 met + SU): A randomised controlled trial Diabetologia 2009 52 2046 2055 19688338
   PubMed Web of Science ®Google Scholar
• Madsbad S Schmitz O Ranstam J Jakobsen G Matthews DR Improved glycemic control with no weight increase in patients with Type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211) Diabetes Care 2004 27 1335 1342 15161785
   PubMed Web of Science ®Google Scholar
• Feinglos MN Saad MF Pi-Sunyer FX An B Santiago O Effects of liraglutide (NN2211), a long-acting GLP-1 analogue, on glycaemic control and bodyweight in subjects with Type 2 diabetes Diabet Med 2005 22 1016 1023 16026367
   PubMed Web of Science ®Google Scholar
• Jendle J Nauck M Matthews D Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for Type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue Diabetes Obes Metab 2009 11 1163 1172 19930006
   PubMed Web of Science ®Google Scholar
• Pratley R Toft A Falahati A Plutzky J P3-431: The once-daily human GLP-1 analog liraglutide significantly improves total cholesterol and the prevalence of metabolic syndrome in Type 2 diabetes: A meta-analysis of six clinical trials Abstract presented at the 2009 annual meeting of the Endocrine Society Washington DC June 10–13, 2009
   Google Scholar
• Courrèges J Vilsbøll T Zdravkovic M Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes Diabet Med 2008 25 1129 1131 19183322
   PubMed Web of Science ®Google Scholar
• Astrup A Rössner S Van Gaal L Effects of liraglutide in the treatment of obesity: A randomised, double-blind, placebo-controlled study Lancet 2009 374 1606 1616 19853906
   PubMed Web of Science ®Google Scholar
• Finer N Al Hakim M Van Gaal L The once-daily human GLP-1 analog liraglutide reduces the prevalence of prediabetes and improves systolic blood pressure in obese non-diabetic subjects: A 52-week randomized placebo-controlled trial Obesity 2009 17 S108
   Web of Science ®Google Scholar
• Nauck MA Ratner RE Kapitza C Berria R Boldrin M Balena R Treatment with the human once-weekly glucagon-like peptide-1 analog taspoglutide in combination with metformin improves glycemic control and lowers body weight in patients with Type 2 diabetes inadequately controlled with metformin alone Diabetes Care 2009 32 1237 1243 19366970
   PubMed Web of Science ®Google Scholar
• Rosenstock J Reusch J Bush M Yang F Stewart M Potential of albiglutide, a long-acting GLP-1 receptor agonist, in Type 2 diabetes Diabetes Care 2009 32 1880 1886 19592625
   PubMed Web of Science ®Google Scholar
• Day JW Ottaway N Patterson JT A new glucagon and GLP-1 co-agonist eliminates obesity in rodents Nat Chem Biol 2009 5 749 757 19597507
   PubMed Web of Science ®Google Scholar
• Pocai A Carrington PE Adams JR Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice Diabetes 2009 58 2258 2266 19602537
   PubMed Web of Science ®Google Scholar